Gastroenterology practices face a distinctive trio of administrative challenges: colonoscopy prep communication failures that result in inadequate bowel preparation and procedural cancellations, biologic authorization complexity for inflammatory bowel disease patients that rivals oncology in documentation burden, and pathology result workflows where delays can mean delayed cancer diagnoses. Virtual assistants trained in GI operations are addressing all three with systematic, scalable workflows that protect both patient outcomes and practice revenue.
Colonoscopy Prep Communication Directly Impacts Procedure Completion Rates
The American College of Gastroenterology (ACG) estimates that 15 million colonoscopies are performed annually in the United States, making it one of the most commonly performed GI procedures. Yet inadequate bowel preparation — resulting from incomplete prep instructions, patient confusion about low-residue diet requirements, or failure to follow split-dose protocols — leads to procedure cancellation or incomplete examination in 20–25% of colonoscopy cases at practices without structured prep communication programs.
Each failed or incomplete colonoscopy represents a direct revenue loss: CMS reimburses colonoscopy procedures at $300–$500 per procedure, and rescheduling adds scheduling burden without adding capacity. ACG quality benchmarks identify inadequate prep as the single most modifiable factor in colonoscopy procedure quality.
A GI VA builds and manages a colonoscopy prep communication sequence — typically 7 days, 3 days, and 1 day before the procedure — using patient outreach tools integrated with Athenahealth, Epic, or Kareo: sending prep instruction packets, confirming that patients have obtained their prep solution, answering logistics questions via secure messaging, and identifying patients who need a prep education call. Practices with VA-managed prep communication programs report adequate bowel preparation rates of 90–95%, versus 75–80% without structured outreach.
IBD Biologic Prior Authorization Is Among the Most Complex in Outpatient Medicine
Biologic therapies for Crohn's disease and ulcerative colitis — infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, ozanimod — represent the fastest-growing segment of GI pharmaceutical spending. Commercial payers and Medicare Part D plans require prior authorization that includes documented disease severity (Harvey-Bradshaw Index, Mayo Score), prior steroid and conventional immunosuppressant trial failure, endoscopic or radiographic evidence of active disease, and in some cases tuberculosis testing results.
ACG data shows that GI practices with active IBD programs submit 30–60 biologic authorization requests per month. MGMA benchmarking indicates that practices without dedicated authorization tracking have initial denial rates of 25–35% for biologic medications — largely due to incomplete documentation rather than clinical ineligibility. Each denied claim requires an appeal process consuming 4–8 additional staff hours.
A GI VA builds a biologic authorization tracker organized by patient, drug, payer, and expiration date. They manage submission through Availity or manufacturer hub services (Janssen CarePath, AbbVie myAbbVie Assist), compile clinical documentation packages from Epic or Athenahealth, track approval timelines, and initiate reauthorization workflows 45 days before coverage expires. The result is measurably lower denial rates and near-elimination of coverage gaps that interrupt IBD treatment.
Pathology Tracking From GI Procedures Requires Systematic Follow-Up
Colonoscopy, upper endoscopy, and EUS-guided biopsies generate pathology specimens that must be tracked from collection through report receipt, physician review, patient notification, and follow-up scheduling. When this workflow is informal — relying on individual staff members to monitor the pathology inbox — results fall through the cracks. For GI pathology, the stakes are high: a missed colon adenocarcinoma pathology report or a delayed dysplasia result in a Barrett's esophagus patient is a patient safety event.
ACG guidelines require timely pathology result notification and appropriate follow-up surveillance scheduling. MGMA data shows practices with defined pathology result tracking protocols have lower rates of delayed critical result notification than those without defined workflows.
A GI VA monitors the pathology result queue in the practice EHR, flags critical or unexpected results for immediate physician review per a defined protocol, sends patient notification communications according to practice policy, and schedules follow-up surveillance colonoscopies at the interval recommended in the pathology report. This systematic approach closes the administrative loop on every biopsy taken — at a fraction of the cost of the clinical time it would otherwise require.
Protecting GI Practice Revenue and Patient Outcomes
ACG projects continued growth in GI disease burden, particularly colorectal cancer screening demand driven by updated guidelines recommending screening initiation at age 45. Practices that build VA-supported administrative infrastructure now will absorb that demand without proportional cost growth. Stealth Agents provides GI-trained VAs matched to Athenahealth, Epic, and Kareo workflows.
Sources
- American College of Gastroenterology (ACG). ACG 2025 Quality Indicators for Colonoscopy and IBD Management. gi.org
- MGMA. Gastroenterology Practice Operations Benchmark Report 2025. mgma.com
- CMS. Colorectal Cancer Screening Coverage and Reimbursement Guidelines. cms.gov
- Janssen CarePath. IBD Patient Support and Prior Authorization Hub Services. janssen.com